<DOC>
	<DOCNO>NCT00855205</DOCNO>
	<brief_summary>Sarcoidosis inflammatory disease affect many part body , especially lung . While patient well , group patient require continuous dos prednisone drug . The current study determine role Rituximab new agent patient refractory disease .</brief_summary>
	<brief_title>Rituximab Pulmonary Sarcoidosis</brief_title>
	<detailed_description>Patients refractory pulmonary sarcoidosis eligible participation open label trial Rituximab additional therapy . The study evaluate efficacy rituximab improve symptom functional capacity patient chronic sarcoidosis pulmonary involvement symptomatic despite current treatment .</detailed_description>
	<mesh_term>Sarcoidosis</mesh_term>
	<mesh_term>Sarcoidosis , Pulmonary</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>1 . Men woman &gt; 18 year age . 2 . Sarcoidosis diagnose least 1 year prior screen . 3 . Histological proven sarcoidosis prior screen . 4 . Have diagnosis severe sarcoidosis evidence parenchymal disease chest radiograph ( Stage III ) abnormal PFT , histologic evidence sarcoid ( involvement biopsy ( pulmonary extrapulmonary ) ) . Subjects concurrent extrapulmonary sarcoidosis particularly skin eye involvement encourage enrol . Patients neurologic sarcoidosis exclude . 5 . Have FVC &gt; 40 &lt; 80 % predict . 6 . Have ATS dyspnea score &gt; Grade 1 . 7 . Have receive prestudy treatment include least 10 mg/day prednisone equivalent dose corticosteroid single agent , and/or methotrexate , hydroxychloroquine least 3month period prior screen . Subjects must stable dose med &gt; 4 week start study medication . 8 . Adequate birth control measure ( e.g . abstinence , oral contraceptive , intrauterine device , barrier method spermicide , surgical sterilization ) must use duration study continue precaution 6 12 month receive last study infusion . 9 . Are consider eligible base TB screen . 10 . Are capable read understand subject assessment form provide write informed consent . 11 . Are willing able adhere study visit schedule protocolspecified procedure . Laboratory Exclusion Criteria 1 . Hemoglobin : &lt; 8.5 gm/dL 2 . Platelets : &lt; 100,000/mm 3 . Serum Creatinine : &gt; 1.4 4 . Neutrophils : &lt; 1.5 x mm3 5 . IgG : &lt; 5.6 mg/dl IgM : &lt; .55 mg/dl 6 . AST ALT &gt; 2.5 x Upper Limit Normal unless related primary disease . 7 . Positive Hepatitis B C serology ( Hep B surface antigen Hep C antibody ) General Safety Exclusion Criteria 1 . Previous Treatment Rituximab ( MabThera® / Rituxan® ) 2 . Previous administration treatment therapeutic agent target deplete B cell within 12 month prior screen . 3 . Treatment investigational agent within 4 week screen 5 halflives investigational drug ( whichever longer ) 4 . Current treatment TNF inhibitor , cyclosporine , tacrolimus leflunomide . 5 . Treatment TNF inhibitor within ( 8 week prior screen ) , cyclosporine tacrolimus ( 4 week prior screen ) leflunomide ( 8 week prior screen , 25 day cholestyramine washout ) . 6 . Previous treatment within 6 month IVIg . 7 . Parenteral corticosteroid within 4 week prior screen visit . 8 . Receipt live virus bacterial vaccination within 4 week first dose study agent expect receive live virus bacterial vaccination trial 3 month last dose study agent 9 . History severe allergic anaphylactic reaction associate administration humanize murine monoclonal antibody 10 . History New York Heart Association ( NYHA ) Class III IV congestive heart failure ( CHF ) 11 . History severe rightsided heart failure cor pulmonale 12 . Known active bacterial , viral , fungal mycobacterial , infection ( include tuberculosis atypical mycobacterial disease , exclude fungal infection nail bed ) major episode infection require hospitalization treatment i.v . antibiotic within 2 month screen oral antibiotic within 2 week prior screen 13 . History recurrent significant infection history recurrent bacterial infection 14 . History opportunistic infection ( e.g. , herpes zoster [ shingle ] , cytomegalovirus , Pneumocystis carinii , aspergillosis aspergilloma , histoplasmosis , mycobacteria TB ) within 6 month prior screen 15 . History known infection human immunodeficiency virus ( HIV ) 16 . Considered ineligible accord USAspecific TB screen 17 . Pregnancy ( negative serum pregnancy test perform woman childbearing potential within 7 day treatment ) lactation 18 . Current sign symptom systemic lupus erythematosus , severe , progressive , uncontrolled renal , hepatic , hematologic , endocrine , pulmonary , cardiac , neurologic , cerebral disease ( exception sarcoidosis ) . 19 . Have normal pulmonary function 20 . Have clinical evidence intracranial lesion . 21 . Have abnormal neurological examination baseline assessment 22 . Have neurosarcoidosis 23 . Have know history demyelinate disease multiple sclerosis optic neuritis . 24 . Concomitant malignancy previous malignancy , exception adequately treat basal squamous cell carcinoma skin carcinoma situ cervix . 25 . Have poor tolerability intravenous infusion lack adequate venous access require blood sample . 26 . History transplant organ ( exception corneal transplant &gt; 3 month prior screen . 27 . History substance abuse dependency , drug alcohol within 3 year screen 28 . History primary secondary immunodeficiency 29 . History psychiatric disorder would interfere normal participation protocol 30 . Any disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug may affect interpretation result render patient high risk treatment complication . 31 . Inability comply study followup procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>pulmonary sarcoidosis</keyword>
</DOC>